Gene Therapy Breakthrough Offers Hope for Bardet-Biedl Syndrome Patients
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), the promise of gene therapy continues to grow. Recent advancements highlight significant strides in treating rare conditions like Bardet-Biedl syndrome (BBS), offering renewed hope for preserving vision and improving quality of life.
Bardet-Biedl syndrome is a complex, rare genetic disorder affecting approximately 1 in 100,000 to 150,000 births, characterized by a range of symptoms including obesity, kidney dysfunction, and progressive vision loss that often leads to blindness by early adulthood. It can be caused by mutations in over 20 different genes. The vision impairment in BBS is a form of inherited retinal disease, where the light-sensitive cells in the retina gradually degenerate.
Pioneering Gene Therapy for BBS10-Related Vision Loss
A significant development in the field comes with the news that an 11-year-old girl in the UK, Catherine L'Estrange, became the first patient in the country, and only the second worldwide, to receive an experimental gene therapy for BBS. Catherine was diagnosed with BBS caused by mutations in the BBS10 gene, which is the second most common form of BBS. This groundbreaking procedure, performed at St. Helier Hospital in London, involves injecting healthy copies of the BBS10 gene directly into the retina.
The gene therapy, developed by MeiraGTx, aims to stabilize or even improve vision by delivering a working version of the BBS10 gene to the eye cells. Catherine's father expressed the family's surprise and delight, as they had previously been told that such a treatment was many years away and likely to arrive after Catherine had already lost her sight. This treatment is designed to intervene before complete vision loss occurs, offering a critical window of opportunity for patients. The first patient to receive this therapy was a 17-year-old Canadian girl treated in August 2025 at the same hospital.
Impact and Future Outlook
The experimental treatment for BBS highlights the accelerating pace of gene therapy research for IRDs. The procedure itself is a